Your browser doesn't support javascript.
loading
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord, Ian D; Chanez, Pascal; Criner, Gerard J; Kerstjens, Huib A M; Korn, Stephanie; Lugogo, Njira; Martinot, Jean-Benoit; Sagara, Hironori; Albers, Frank C; Bradford, Eric S; Harris, Stephanie S; Mayer, Bhabita; Rubin, David B; Yancey, Steven W; Sciurba, Frank C.
Afiliação
  • Pavord ID; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Chanez P; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Criner GJ; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Kerstjens HAM; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Korn S; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Lugogo N; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Martinot JB; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Sagara H; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Albers FC; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Bradford ES; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Harris SS; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Mayer B; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Rubin DB; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Yancey SW; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
  • Sciurba FC; From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, A
N Engl J Med ; 377(17): 1613-1629, 2017 10 26.
Article em En | MEDLINE | ID: mdl-28893134
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Eosinófilos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Eosinófilos / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article